price close busi juli
gener preview expect less drama
expect much less drama gener group previou quarter
core busi group perform well addit weve seen solid
new product approv flow amneal close anda approv sinc
may newco telig indic potenti strong
compani rais estim endo given solid core busi perform
driven steril inject modestli lower expect ani
meanwhil weve adjust expens expect revenu estim
amneal follow close merger may made modest tweak
aceto telig estim
stori watch watch ani commentari close updat
cortrophin could move share recal ani held type meet fda
march compani littl share may earn updat follow
addit commun agenc expect meati updat timelin
step re-commerci product
acet call tbd cgie revenue/ep factset
consensu expect acet issu guidanc
also expect revenue/ep consensu
call dial
passcod cgie revenue/ep factset
consensu expect revenue/ep
 consensu
call tbd cgie revenue/ep factset
consensu expect revenue/ep mm/
 consensu
call dial
passcod cgie revenue/ep factset
consensu expect revenue/ep
consensu
call dial
passcod cgie revenue/ep factset
consensu expect revenue/ep mm/
 consensu
tlgt call tbd cgie revenue/ep factset
consensu expect revenue/ep mm/
 consensu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
ep date tbd like
wait strateg clariti jump
think clariti compani go-forward strategi import convey
fiscal year-end call aceto aclari busi score victori court allow
access va also dod system think total bottom-lin impact
busi rel small
confid ceo kennal team run establish gener
busi see acet share uninvest given on-going
strateg review process potenti bad news due compani
asset-light oper model team right ship
 guidanc street
expect report
guidanc consensu
updat strateg review process potenti divestitur
clariti impact recent aclari va win
thought tariff polici impact specialti chemic busi
key controversi stori
potenti divestitur busi rais cash
busi challeng price margin
chang estim
figur chang aceto revenu ep estim
price target deriv dcf analysi estim weight averag
cost capit wacc assum equiti structur
equiti cost capit along debt structur cost debt use
long-term estim tax rate analysi conserv
appli benefit net oper loss futur tax liabil
risk rate price target
best case scenario conting upon potenti transaction-driven cash
gener quick strateg shift may spell turn-around acet share
compani gener portfolio continu feel signific pressur well-season
manag team may elect pursu altern rout busi strategi
sever aceto gener peer undertaken
aceto may need sell asset cash gener purpos
given near-term financ concern continu headwind gener
portfolio manag may elect sell asset segment busi nt
cash relief mean pivot strategi quickli
aceto may choos liquid compani seek transact
part on-going strateg review aceto may elect liquid compani
merg anoth compani potenti gener return sharehold
current dcf-driven valuat
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
fiscal year end june thousand usd except per share lrevenuehuman profit oper expensescost oper expensesinterest incom expens net incomeincom tax analysisbas share share per figur aceto dcf model
thousand usd except per share amount fy end depreci amort excl chang growth estim period long-term period net debt share outstand specialti
ep report august
market open call et dial
id
messi integr quarter encourag potenti new product flow
like see messi quarter follow earli may merger close given
partial quarter contribut busi street estim fairli wide
close gener approv us sinc deal close
newco expect solid perform addit wed expect guidanc
clariti well
 guidanc street
expect report
like see sever closing-rel charg disconnect
adjust ep
updat guidanc follow string new product approv could launch
commentari gener price environ
thought potenti busi develop
key controversi stori
string new product approv set compani nice growth go
forward
compani reach manag initi target double-digit
revenu ep growth
what next acquisit
specialti brand fit stori
chang estim
figur chang amneal revenu ep estim
price target deriv dcf analysi consid wacc
risk rate price target
sever downsid risk could lead us re-evalu posit view
amneal includ potenti nt distract relat impax/amn
integr continu macro micro price challeng gener industri
regulatori complianc issu potenti gener competit amneal
brand product expect growth rate well compani peer
addit could becom construct share attract
entri point determin signific pullback share driven
ephemer concern like price custom consolid competit launch
caus signific volatil group tangibl evid growth profil well
amneal peer
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
thousand usd except per share pharma profit oper expensescost legal develop reimburs unit litig settlement contract asset impair oper expensesinterest hedg debt sale certain intern non-oper net income-incom tax analysisfd share share figur amneal dcf model
thousand usd except per share depreci amort exclud chang growth estim period long-term period net debt share outstand specialti pharmaceut
ep report tbd like week
august
cortrophin expect key foci
given saw partial updat cortrophin follow ani fda meet earlier
year expect addit clariti compani step timelin
re-commerci encourag recent deal acquir sever
gener product divest impax/amn merger interest
impact guidanc expect transact
 guidanc street
expect report
cortrophin commentari current state recommerci
thought impact impax/amn product
updat guidanc
key controversi stori
long take bring cortrophin market process
solid busi develop effort ad interest tail product
unapprov product make larg chunk gener busi
chang estim
figur chang ani revenu ep estim
price target deriv dcf assum wacc termin
risk rate price target
corticotrophin develop consum signific compani resourc
ani recent acquisit corticotrophin asset merck potenti posit
compani well brand altern acthar gel beyond initi
acquisit cost believ ani spend signific resourc next
sever quarter bring corticotrophin back market us guarante
price gener industri highli competit
compani gener industri compet number differ factor
includ product select manufactur technolog corpor reput
product price price gener industri tend cyclic compani
particip us gener market observ higher-than-norm price
pressur major product form present gener
compani us must overcom higher-than-norm price eros gener
us gener manufactur market subject strict regulatori control
like brand counterpart compani particip us gener
pharmaceut market must adher strict regulatori control develop
manufactur market ani subject fda regul chang fda
structur polici procedur could neg affect ani busi prospect
littl visibl ani gener pipelin could depress valuat estim
ani oper highli competit industri gener littl visibl
compani pipelin futur launch plan disclosur may dilut
impact ani launch market given limit concret visibl ani
runway growth expect investor may discount uncertainti share
gener competit may emerg ani brand product
ani sell sever brand product littl gener competit
gener expect littl interest gener product addit
gener competit could emerg one ani brand product reduc
revenu profit ani
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
thousand usd except per share lrevenuegener profit oper expensescost charg -- -- -- -- -- -- -- -- -total oper expensesinterest expens expense/incom net incomeincom tax analysisbas share share figur ani dcf model
thousand usd except per share servic exclud -- -- -- -- -- -- -- -- -- -- chang growth estim period long-term period net debt share outstand specialti pharmaceut
ep report august
market open call et dial
id
stori continu come togeth
endo stori continu come togeth nice gener busi continu
perform well despit challeng macro trend believ endo report
decent quarter rel expect weve seen strong volum trend third
parti sourc key product
 guidanc street
expect report
updat cch program on-going phase studi cellulit
updat guidanc follow appear solid volum price trend
thought pend litig especi opioid
key controversi stori
litig overhang especi opioid could weigh cash flow
manag done excel job refin gener busi
product driver unclear propel growth
chang estim
figur chang endo revenu ep estim
price target deriv dcf analysi assum wacc
risk rate price target
despit posit price action certain area endo gener portfolio
endo base gener busi face double-digit price eros
difficult new launch overcom
littl visibl endo gener pipelin
expect highly-competit gener leader endo give littl clariti
compani gener pipelin give substanti detail upcom
launch see believ difficult endo pipelin
off-set price challeng base gener portfolio
brand pipelin wipe strateg realign
endo signific brand pipelin asset xiaflex cellulit believ
product could approv indic endo brand team littl
experi dermatolog aesthet space believ compani
either construct new commerci structur support cellulit launch
endo find partner space dilut econom product
endo oper regul environ
pharma compani oper us countri endo subject fda
regul particularli gener portfolio chang fda structur polici
procedur could neg impact endo busi prospect
vasostrict surpris inject asset substanti durabl
model gener like competitor launch endo may
exclus multi-hundr million dollar product well time-frame
addit recent approv upcom launch corphedra could help buffer
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
thousand usd except per share lrevenueu brand steril gener profit oper expensescost conting net -- -- -- -- -- -- -- -- -- -asset impair charg -- -- -- -- -- -- -- -- -- -acquisition-rel integr item -- -- -- -- -- -- -- -- -- -total oper expensesinterest expens extinguish debt -- -- -- -- -- -- -- -- -- -other incom /expens net incomeincom tax oper net tax -- -- -- -- -- -- -- -- -- -non-control analysisbas share share figur endo dcf model
million usd except per share brand gener depreci amort excl chang growth estim period long-term period net debt legal accrual share outstand specialti pharmaceut
ep report august
market open call et dial
id
gener strategi like investor sight
unlik get color new manag strateg thought
like save fall investor day wed appreci clariti perrigo
evolut consumer-driven busi said gener wed like
clariti launch expect especi proair pictur well
look guidanc updat follow delay
 guidanc street
expect report
wed like updat strateg review unlik get
updat effort remedi intern busi
thought effort bring gener proair market
hint profil gener busi
key controversi stori
manag appear posit compani consum name
top bottom line growth lower specialti pharma peer
new manag reluct share strateg vision
slow consist growth great pharma investor typic demand
pure-play consum stori without gener compon
chang estim
figur chang revenu ep estim
price target deriv dcf consid wacc
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand ep report tbd like week
august
manag take solid step posit stori
weve encourag manag effort address convert
note well watch addit step address remaind issu
think updat bring buena inject expans line
import investor see inject solid potenti sourc growth
face increas competit topic space howev telig post
strong string recent topic approv curiou impact
 guidanc street
expect report
updat buena progress product launch timelin
addit color complex product compani develop
updat guidanc follow string recent product approv
updat financi strategi
key controversi stori
new product approv flow set compani nice valu creation
buena valid critic propel growth difficult process
chang estim
figur chang telig revenu ep estim
discount cash flow dcf analysi lead us price target
tlgt share dcf consid estim termin
growth thereaft addit expect telig margin structur gener
estim weight averag cost capit wacc higher
compani within telig peer set given compani near-term cash
challeng use long-term estim tax rate analysi
risk rate price target
upsid telig product launch flow profit could pick next
telig growth depend new launch replac revenu lost
competit core busi telig abl pick pace new
launch bring uniqu complex product market valuat may increas
estim
downsid telig reliant partner manufactur sever import
product work expand manufactur facil subject regulatori review
compani manufactur capabl topic dermatolog
product mani high-growth product compani portfolio steril inject
compani current reliant manufactur partner
time telig embark manufactur expans bring steril inject
manufactur hous expans subject close regulatori review
could delay facil process found complianc
downsid telig fraction size mani competitor
telig small size great opportun compani grow time
telig may disadvantag consolid custom landscap mani
competitor broad scale across mani telig product larger
competitor may abl leverag scale custom receiv
favor price posit rel telig
downsid price gener industri highli competit
compani gener industri compet number differ factor
includ product select manufactur technolog corpor reput
product price price gener industri tend cyclic compani
particip us gener market observ higher-than-norm price
pressur major product form present gener
compani us must overcom higher-than-norm price eros gener
downsid us gener manufactur market subject strict
like brand counterpart compani particip us gener
pharmaceut market must adher strict regulatori control develop
manufactur market telig subject fda regul chang
fda structur polici procedur could neg affect telig busi
downsid littl visibl telig gener pipelin could depress valuat
estim tlgt share
telig oper highli competit industri gener littl visibl
compani pipelin futur launch plan disclosur may dilut
